Clinical trials: Castrate-resistant Prostate Cancer
Prostate Cancer
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line…
- Trial name
- SYNERGY (NCT01188187)
- Testing
- Custirsen, Docetaxel, Prednisone
- Where
- 140 sites in United States, Belgium and 10 more
- Volunteers
- 1,022 people
- Sponsor
- Achieve Life Sciences
Prostatic Neoplasm
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer…
- Trial name
- PROter (NCT03490838)
- Testing
- 177Lu-PSMA-R2
- Where
- 11 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- Advanced Accelerator Applications
Prostate Cancer
Assessment of New Molecular Imaging Strategies for Prostate Cancer
In this study 30 men, with advanced metastatic Castration-Resistant Prostate Cancer (CRPC) planned to have hormonal treatment, will undergo conventional imaging and functional imaging prior to treatment and post treatment to…
- Trial name
- MISTER (NCT02813226)
- Testing
- Molecular Imaging
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.
- Trial name
- NCT00585416
- Testing
- CGC-11047
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Wisconsin, Madison
Bone Metastatic Castration-Resistant Prostate Cancer
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
This study will examine biomarkers involved in osteomimicry in bone metastases and circulating tumor cells (CTCs) of men with mCRPC before and during therapy with the bone-targeting radiopharmaceutical radium-223.
- Trial name
- NCT02204943
- Testing
- Biomarker analysis, Administration of radium-223
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Castration-resistant Prostate Cancer
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT02207504
- Testing
- Crizotinib, Enzalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Castration-resistant Prostate Cancer
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response.
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT05081193
- Testing
- Testosterone Undecanoate, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castration Resistant Prostate Cancer
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
After failure of initial ADT, addition of an anti-androgen is established to treat castration resistant prostate cancer (CRPC). Substitution of the first anti-androgen and anti-androgen withdrawal results in treatment responses…
- Trial name
- NCT01646684
- Testing
- SOM230
- Where
- 4 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Castration Resistant Prostate Cancer
A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer
When metastatic prostate cancer becomes unresponsive to hormone therapy, it is known as castration resistant prostate cancer, treatment options are limited and response to this treatment can be short.
- Trial name
- TRICREST (NCT07161778)
- Testing
- Triamcinolone acetonide IM injection
- Where
- 3 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- Barts & The London NHS Trust
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostatic Neoplasms, Neoplasms, Hormone-Dependent
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are…
- Conditions
- Prostatic Neoplasms, Neoplasms, Hormone-Dependent, Tumor Markers, Biological, Survival Rate
- Trial name
- PROSUT (NCT00748358)
- Testing
- sunitinib
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
Checkpoint Inhibitors and SBRT for MCRPC
The goal of this investigator-initiated, single-center, and randomized phase II trial is to investigate the potential synergistic effect of combining stereotactic body radiotherapy of a single soft tissue- or bone metastasis with…
- Conditions
- Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Stage IV
- Trial name
- CheckPRO (NCT05655715)
- Testing
- Stereotactic body radiotherapy, Ipilimumab Injection [Yervoy], Nivolumab Injection [Opdivo]
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Herlev and Gentofte Hospital
Castration-Resistant Prostatic Cancer
An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine Care
The aim of this study is to assess the effectiveness of 177Lu-PSMA-617 (lutetium (177Lu) vipivotide tetraxetan) on survival in patients randomized to receive treatment following progression on one ARPI from the PSMAfore trial…
- Trial name
- NCT07843758
- Where
- Switzerland
- Volunteers
- 1,525 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
This is a randomized, open-label study designed to assess the effects of sipuleucel-T when administered concurrently or sequentially with enzalutamide.
- Trial name
- NCT01981122
- Testing
- sipuleucel-T, enzalutamide
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dendreon
Metastatic Castration-Resistant Prostate Cancer Patients
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
- Trial name
- NCT07135102
- Testing
- 225Ac-PSMA-XT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiaorong Sun
Prostate Cancer
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
PSMA is an ideal target for the precise diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted compound.
- Trial name
- NCT07363486
- Testing
- 225Ac-LNC1011
- Where
- China
- Volunteers
- 9 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic).
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT01503229
- Testing
- Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Metastatic Castration-resistant Prostate Cancer
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal…
- Trial name
- NCT07142551
- Testing
- Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Men with progressive metastatic Castration-Resistant Prostate Cancer post first-line treatment with either androgen deprivation therapy alone or androgen deprivation therapy plus docetaxel who have an identified related female…
- Trial name
- NCT02995330
- Testing
- Bone marrow transplantation, Cytoxan, testosterone cypionate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084565
- Testing
- estramustine phosphate sodium, paclitaxel, topotecan hydrochloride
- Sponsor
- Fox Chase Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.